Bridgeford is pleased to announce that in representing Elastrin Therapeutics Inc., a privately held biotechnology company, we assisted them closing a $10 million funding round led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies.

For more in-depth on this successful funding round, click here and read through the press release from Kizoo Technology Capital.